Traws Pharma advances dual-strike broad-spectrum antiviral program targeting Hantavirus and Ebola outbreaks

Traws Pharma Inc - to Develop Local Manufacturing in Nigeria With Nafdac

Traws Pharma Inc - Plans Interactions With Cdc, Nafdac, AMA to Fast-Track Development

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Traws Pharma sets up at-the-market equity offering of up to $3.13 million

BRIEF-Traws Pharma Inc Files For Offering Of Up To $3.1 Million In Common Stock

Traws Pharma Inc - Files for Offering of up to $3.1 Mln in Common Stock - SEC Filing

FACTBOX-Hantavirus vaccines and treatments under development

Traws Pharma Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Traws Pharma Q1 EPS $(0.53) Beats $(0.56) Estimate

Traws Pharma Q1 FY26 net loss widens to $7.1 million; R&D expense rises to $4.9 million

Traws Pharma Inc: Traws Plans to Move Rapidly to Advance Clinical Candidate for Hantavirus Treatment

Traws Pharma Inc Q1 Revenue USD 0

Press Release: Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

Here's how much Moderna's stock has rallied off renewed focus on hantavirus research

Traws Pharma Inc expected to post a loss of 74 cents a share - Earnings Preview

Traws Pharma files to sell 35.9M shares of common stock for holders

Sector Update: Healthcare Stocks Lower in Afternoon Trading

There are no hantavirus treatments. The deadly cruise-ship outbreak is a 'wake-up call' to develop some.

Traws Pharma Expands Antiviral Program to Target Hantavirus Infections; Shares Up Pre-Bell